Search Bar & Filters
Found 5 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the effectiveness and safety of lebrikizumab, a drug given by injection, in people aged 12 and older with chronic rhinosinusitis and nasal polyps who are also treated with intranasal corticosteroids. This phase 3 trial aims to improve symptoms like nasal congestion and polyp size while monitoring participant safety over about 18 months. Participants receive lebrikizumab injections on different schedules or placebo injections, all along with standard intranasal corticosteroid spray. Adolescents aged 12 to under 18 who weigh at least 40 kg are assigned to open-label lebrikizumab treatment. The study includes multiple groups receiving injections every 2, 4, or 8 weeks to compare outcomes. During the study, participants will undergo assessments including nasal congestion scoring, endoscopic evaluation of nasal polyps, sinus imaging, lung function tests, and symptom questionnaires from the start through 24 weeks. Safety and symptom changes are closely monitored, and the total study duration is approximately 18 months.
Actively Recruiting
Researchers are investigating how emotional distress ED affects treatment outcomes in patients with metastatic breast cancer mBC who are receiving first-line therapies. This study focuses on the impact of baseline emotional distress on the effectiveness of various treatments according to breast cancer subtypes. Emotional distress is common among breast cancer patients and has been linked to poorer treatment adherence and quality of life, but its role in metastatic breast cancer treatment success is not well understood. Participants will be grouped based on their breast cancer subtype and receive standard first-line treatments accordingly triple-negative PD-L1 positive patients receive chemotherapy with immune checkpoint inhibitors, triple-negative PD-L1 negative patients receive chemotherapy alone, HR-positiveHER2-negative patients receive a CDK46 inhibitor plus endocrine therapy, and HER2-positive patients receive chemotherapy combined with trastuzumab and pertuzumab. Emotional distress and quality of life will be assessed through questionnaires at baseline and during treatment. During the study, patients will complete specific questionnaires to measure emotional distress, quality of life, and fear of cancer progression. Researchers will monitor progression-free survival and objective response rates over two years, comparing outcomes based on emotional distress levels at the start and early in treatment. Quality of life and psychological factors will also be evaluated over three months. All participants must provide informed consent and meet eligibility criteria before joining.
Actively Recruiting
Researchers are observing adult patients with cervical disc herniation and chronic discogenic neck pain who receive intradiscal radiopaque gelified ethanol Absolute Gel as part of routine clinical care. This study describes the clinical and functional course of these patients without assigning any treatment, aiming to collect data on outcomes and safety over a long-term follow-up. The study is non-interventional and collects both retrospective and prospective data from routine practice. Participants receive intradiscal injection of Absolute Gel, a CE-marked Class III medical device, injected at the cervical level under fluoroscopic guidance using an antero-lateral approach with local anesthesia. The study does not impose or modify the treatment or follow-up, and includes patients treated according to physician decisions. The single cohort includes patients already treated and those prospectively treated, with no control or placebo groups. Participants are monitored with clinical and radiological evaluations, including neck pain intensity measured by the Visual Analogue Scale VAS at baseline and multiple follow-ups up to 48 months after treatment. Additional assessments include cervical function scales, medication use, adverse events, and imaging findings as part of routine care. The main outcome is the proportion of participants achieving at least 30% reduction in neck pain at 1 month, with data collected prospectively and retrospectively to understand long-term effects and safety.
Actively Recruiting
Researchers are evaluating a cardiogenic shock protocol designed to improve communication and collaboration among hospitals to timely refer cardiogenic shock patients from spoke to hub centres in the Turin and Milan metropolitan areas. This observational study includes both a retrospective cohort from 2016 to 2019 and a prospective cohort starting in 2024. The purpose is to assess whether implementing this dedicated protocol reduces in-hospital or 30-day mortality in patients with acute myocardial infarction complicated by cardiogenic shock AMICS. Cardiogenic shock is a critical condition requiring rapid intervention and specialized care, and the study focuses on improving outcomes by optimizing patient transfer and treatment coordination. The study compares two groups one retrospective group of patients admitted before the protocol was implemented, and one prospective group admitted after the protocol adoption. Patients in the prospective cohort are managed under a standardized communication and referral protocol between spoke and hub centres, which include advanced cardiac interventions such as percutaneous mechanical circulatory support and prompt transfer to specialized teams. Hub centres have multidisciplinary shock teams, cardiac surgery backup, and 247 availability of cardiac care services. Spoke centres provide initial care and stabilization. The study involves 16 centres, with four hubs each receiving patients from three spoke centres. Participants will be monitored during their hospital stay and followed up to 30 days from admission. Data collected include clinical characteristics, treatments, timing of mechanical support device insertion, adverse events, and outcomes like mortality, stroke, bleeding, renal replacement therapy, vascular complications, and myocardial infarction. The study uses electronic health records and prospectively collected data, with no changes to standard care. The primary measure is 30-day mortality, and secondary outcomes include various clinical events and timing metrics related to treatment support. The study aims to provide insight into whether the hub-and-spoke protocol improves survival and quality of care for cardiogenic shock patients.
Actively Recruiting
Researchers are evaluating how a Modified Mediterranean Diet affects the diversity of gut bacteria in patients with metastatic colorectal cancer who are receiving chemotherapy with or without biological agents. The study compares this diet to a typical Western or standard diet to understand its influence on protecting the intestinal barrier and its potential impact on disease side effects and quality of life. Participants will be randomly assigned to one of two groups one following the Modified Mediterranean Diet, which emphasizes high-quality prebiotic fibers but reduces total fiber intake to ease chemotherapy side effects, and the other continuing their usual Western diet. The study includes a screening visit, a baseline visit where nutritional status and various measurements are taken, and follow-up visits approximately every 15 to 21 days. Stool samples will be collected at about 45 days and 90 days after baseline, with radiological re-evaluations performed as part of routine care. During the study, patients will undergo nutritional assessments, blood tests, bioimpedance analysis, and lifestyle evaluations. Researchers will monitor changes in gut microbiota composition, gastrointestinal side effects, and quality of life over time. The primary outcome is the effect of the diet on microbiota after 45 days, with additional measures including changes in microbiome composition and metabolome at baseline, 45 days, and 90 days. The total participation period includes visits up to 90 days after starting the diet intervention.